Changes at Relypsa, Genzyme, Benitec, Genmab, Celsion, Alligator Bioscience – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Chief scientific officer Biotechnology companies Corporate governance Genzyme

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including changes at Relypsa, Genzyme, Benitec, Genmab, Celsion, Alligator Bioscience.

Claire Lockey ​has been named vice president, regulatory affairs at Relypsa​. Lockey will oversee a number of areas, including quality assurance. Before joining Relypsa Lockey worked at Fibrogen, Titan Pharmaceuticals, Layton Bioscience and Connetics.

All 10 current members of the Genzyme​ board of directors have been re-elected at the annual meeting of shareholders. Genzyme also appointed Dennis Fenton​, settling the dispute with Relational Investors, as well as Steven Burakoff ​and Eric Ende​, at the request of Carl Icahn.

Benitec ​has appointed Peter French ​as CEO. French joined Benitec in August 2009 as chief scientific officer and has previously worked at Cryosite, Probiomics and Fermiscan.

Lisa Drakeman ​has retired as CEO of Genmab​. Jan van de Winkel​, the company’s former chief scientific officer, will replace Drakeman, who has also stepped down from the board of directors. Van de Winkel co-founded Genmab and has also worked at Medarex Europe.

Celsion ​has named Jeffrey Church ​as VP and chief financial officer. Church has previously worked as chief financial officer at Alba Therapeutics, Novavax, GenVec and Meridian Medical Technologies.

Sibylle Lenz ​has joined Alligator Bioscience ​as CEO. Earlier in her career Lenz worked at Dako and H Lunbeck.

Related topics Markets & Regulations

Related news

Follow us


View more